{"id":33386,"date":"2024-12-07T19:27:47","date_gmt":"2024-12-07T13:57:47","guid":{"rendered":"https:\/\/www.nextias.com\/ca\/?p=33386"},"modified":"2025-01-28T18:50:29","modified_gmt":"2025-01-28T13:20:29","slug":"domestic-manufacturing-in-pharmaceutical-sector","status":"publish","type":"post","link":"https:\/\/www.nextias.com\/ca\/current-affairs\/07-12-2024\/domestic-manufacturing-in-pharmaceutical-sector","title":{"rendered":"Domestic Manufacturing in Pharmaceutical Sector"},"content":{"rendered":"\n<p><strong>Syllabus :GS 3\/Economy<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>In News<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The Union government has approved a financial outlay of Rs 15,000 crore for the <a href=\"https:\/\/www.nextias.com\/blog\/production-linked-incentive-pli\/\" data-type=\"link\" data-id=\"https:\/\/www.nextias.com\/blog\/production-linked-incentive-pli\/\"><strong>Production Linked Incentive (PLI) scheme<\/strong><\/a><strong> for Pharmaceuticals<\/strong>, aimed at boosting domestic manufacturing.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>India\u2019s Global Role in Pharmaceuticals<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>India is <\/strong>known as the <strong>&#8220;Pharmacy of the World,<\/strong>&#8221; particularly for supplying vaccines, essential medicines, and medical supplies during the COVID-19 pandemic.<\/li>\n\n\n\n<li>The Pharma sector currently contributes to <strong>around 1.72% of the country\u2019s GDP.<\/strong><\/li>\n\n\n\n<li><a href=\"https:\/\/www.nextias.com\/ca\/current-affairs\/29-08-2024\/indias-pharma-sector-to-reach-130-billion-by-2030\"><strong>Pharmaceutical <\/strong><\/a><strong>Exports: <\/strong>Increased by 8.36% from $2.13 billion (July 2023) to $2.31 billion (July 2024).\n<ul class=\"wp-block-list\">\n<li>Exported pharmaceuticals worth $27.85 billion in FY 2023-24, up from $15.07 billion in FY 2013-14.<\/li>\n\n\n\n<li>India <strong>ranks 3rd globally in drug and pharmaceutical production by volume<\/strong>, exporting to 200+ countries.<\/li>\n\n\n\n<li><strong>Top Export Destinations:<\/strong> USA, Belgium, South Africa, UK, and Brazil.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Growth Projections: <\/strong>Expected to reach $100 billion by 2025 with a growth rate of 10-12%.<\/li>\n\n\n\n<li><strong>India\u2019s Biotechnology Sector Growth<\/strong>:\u00a0Increased 13-fold from $10 billion in 2014 to over $130 billion in 2024.\n<ul class=\"wp-block-list\">\n<li>Future Projections: Expected to reach $300 billion by 2030.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>Pharmaceutical Market Growth is driven by metropolitan cities, Tier I cities, and rural markets, each accounting for about 30% of market share.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Challenges<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Quality Concerns<\/strong>: Ensuring consistent quality standards is crucial, particularly for exports to regulated markets.<\/li>\n\n\n\n<li><strong>Price Regulation:<\/strong> Government policies on drug pricing can impact profitability and investment in R&amp;D.<\/li>\n\n\n\n<li><strong>Dependency on Imports:<\/strong> Despite efforts to boost domestic production, India remains dependent on imports for certain APIs and intermediates.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Related Initiatives&nbsp;<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The<strong> Production Linked Incentive (PLI) Schemes<\/strong> in India focus on boosting domestic manufacturing in key sectors<strong>: bulk drugs, pharmaceuticals, and medical devices.&nbsp;<\/strong><\/li>\n\n\n\n<li><strong>PLI Scheme for Bulk Drugs : Financial Outlay:<\/strong> Rs. 6,940 crores\n<ul class=\"wp-block-list\">\n<li><strong>Tenure<\/strong>: FY 2022-2023 to FY 2028-29<\/li>\n\n\n\n<li><strong>Objective<\/strong>: Promote manufacturing of critical Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs).<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>PLI Scheme for Pharmaceuticals : Financial Outlay: <\/strong>Rs. 15,000 crores\n<ul class=\"wp-block-list\">\n<li><strong>Tenure:<\/strong> FY 2022-2023 to FY 2027-2028<\/li>\n\n\n\n<li><strong>Objective<\/strong>: Incentivize manufacturing of high-value pharmaceutical products like patented drugs, biopharmaceuticals, complex generics, anti-cancer drugs, and orphan drugs.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>PLI Scheme for Medical Devices : Financial Outlay:<\/strong> Rs. 3,420 crores\n<ul class=\"wp-block-list\">\n<li><strong>Tenure<\/strong>: FY 2022-2023 to FY 2026-2027<\/li>\n\n\n\n<li><strong>Objective<\/strong>: Support domestic production of high-value medical devices, such as MRI machines, CT scans, and linear accelerators, reducing dependence on imports.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Conclusion and Way Forward&nbsp;<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>India&#8217;s pharmaceutical <\/strong>sector stands as a testament to the country&#8217;s capabilities in innovation, manufacturing, and global healthcare leadership.<\/li>\n\n\n\n<li>With continued support from the government and investments in R&amp;D, the sector is poised to achieve new heights, contributing significantly to both national and global health outcomes.<\/li>\n<\/ul>\n\n\n\n<p class=\"has-background\" style=\"background-color:#ebecf0\"><strong>For More information Refer to <\/strong><a href=\"https:\/\/www.nextias.com\/ca\/current-affairs\/29-08-2024\/indias-pharma-sector-to-reach-130-billion-by-2030\"><strong>India\u2019s Pharma Sector<\/strong><\/a>.<\/p>\n\n\n\n<p><strong>Source :<\/strong><a href=\"https:\/\/pib.gov.in\/PressReleaseIframePage.aspx?PRID=2081491\" target=\"_blank\" rel=\"noopener\"><strong>PIB<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Union government has approved a financial outlay of Rs 15,000 crore for the Production Linked Incentive (PLI) scheme for Pharmaceuticals, aimed at boosting domestic manufacturing.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-33386","post","type-post","status-publish","format-standard","hentry","category-current-affairs"],"acf":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/33386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/comments?post=33386"}],"version-history":[{"count":2,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/33386\/revisions"}],"predecessor-version":[{"id":36335,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/33386\/revisions\/36335"}],"wp:attachment":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/media?parent=33386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/categories?post=33386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/tags?post=33386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}